- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Moderate to severe symptomatic uterine fibroids
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 2.1MB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 2.2MB)
Linzagolix – July 2024
Linzagolix; Tablet 100 mg (as choline), Tablet 200 mg (as choline); Yselty®
Last updated
30 May 2025